Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of VIB9600 by Intravenous Infusion or Subcutaneous Injection in Healthy Subjects

Trial Profile

A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of VIB9600 by Intravenous Infusion or Subcutaneous Injection in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs VIB-9600 (Primary) ; VIB-9600 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; First in man
  • Sponsors Viela Bio
  • Most Recent Events

    • 16 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 13 Dec 2018 Planned number of patients changed from 64 to 80.
    • 20 Aug 2018 According to a Viela Bio media release, this trial will be executed in collaboration with CTI Clinical Trial & Consulting as the CRO.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top